Abstract:Background This article aims to present research pertaining to the effect of angiotensin receptor-neprilysin double blocker on blocking the inflammatory mechanism mediated by NLRP3 inflammasome on hypertensive nephropathy. ARNI has not only been found to improve cardiac function but is also associated with a reduction in progressive deterioration of kidney function owing to hypertension by exerting anti-inflammation, anti-autophagy, anti-fibrosis and anti-Golgi’s apparatus. We hypothesized that administration of ARNI is more effective than valsartan alone in slowing progression of hypertensive renal disease. Methods Rat models with spontaneous hypertension were randomized into a no treatment group, valsartan group (60 mg/kg), ARNI group (70 mg/kg) or ARNI + A779 group (70 mg/kg + 400ng/kg) daily by gavage. Sprague-Dawley rats were subjected to the control conditions (without hypertension and treatment). The kidney tissue analyses were performed after 12 weeks. We detected the expression levels of NLRP3 and casepase-1 in kidney tissue, and NLRP3 levels in human embryonic kidney cells which were induced by ang II as hypertension cell model by Real-Time Polymerase Chain Reaction. To analyze the impact of ARNI on autophagy, we performed western blot analysis on renal tubules to measure the protein expression of NLRP3 inflammasome, and to measure the protein expression of P62 and LC3. Masson 3 staining method was used to stain renal fibrosis. Immunohistochemistry was performed to determine the expression sites of NLRP3. The Golgi apparatus in morphology of renal tubular cells was determined by transmission electron microscope. Results The untreated hypertensive renal disease rats exhibited tubular and glomerular damage, downregulation of pro-inflammatory, pro-autophagy, pro-fibrotic and pro-Golgi’s apparatus pathways. ARNI administration improved renal function and histology changes and attenuated most of the molecular markers of inflammation, autophagy, fibrosis and Golgi’s apparatus. Conclusions ARNI activation attenuates renal complications of arterial hypertension by reduction of kidney inflammation through selective actions requiring the renal tubular epithelium but not the glomerular endothelial cells and the circumferential mesangial interposition cell Angiotensin Receptor. ARNI was more effective than valsartan therapy alone in delaying the progression of hypertensive renal disease.

Angiotensin Receptor-Neprilysin Inhibition (Sacubitril/Valsartan) Reduces Structural Arterial Stiffness in Middle-Aged Mice

Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model

Sacubitril/Valsartan Alleviates Cardiac Remodeling and Dysfunction in L-NAME-Induced Hypertension and Hypertensive Heart Disease

Effects of sacubitril-valsartan on aging-related cardiac dysfunction

Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure

Smooth Muscle Cell-Mineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging

Cellular Senescence Contributes to Large Elastic Artery Stiffening and Endothelial Dysfunction With Aging: Amelioration With Senolytic Treatment

Abstract 186: Superiority of Sacubitril/Valsartan Over Valsartan Alone in Attenuating Pressure Overload-induced Cardiac Fibrosis and Oxidative Stress

Abstract 8929: Mineralocorticoid Receptor As an Epigenetic Regulator of Vascular Aging

The Impact of Sacubitril/Valsartan on Cardiac Fibrosis Early after Myocardial Infarction in Hypertensive Rats.

Angiotensin II Type 1 Receptor Blockers Prevent Aortic Arterial Stiffness in Elderly Patients with Hypertension

Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy

Chronic angiotensin converting enzyme inhibition attenuates frailty and protects against atrial fibrillation in aging mice

Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet

Aging impairs smooth muscle-mediated regulation of aortic stiffness: a defect in shock absorption function?

Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals

Angiotensin Receptor Neprilysin Inhibition mediates Renal Protection by ARNI (Sacubatril Valsartan) in Rats with Spontaneous Hypertension

Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF

Abstract 16975: Wheel-Running Exercise Abrogates Enhanced Sympathetic Neural-Immune Interface in Aortic Adventitia of Angiotensin II-Infused Hypertensive Mice

The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond

N-acetyl Cysteine Ameliorates Aortic Fibrosis by Promoting M2 Macrophage Polarization in Aging Mice